Targeting neurological disorders with antisense oligonucleotides

Richard A. Smith, Timothy M. Miller

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations

Abstract

Neurological disorders represent a major health burden that is increasing in magnitude in parallel with the demographic shift in the age of the population of advanced societies. In the United States alone it is estimated that 3.5 million people are afflicted with Alzheimer’s disease, which typically runs its fatal course over 3-5 years [1]. While advances in medicine have been one of the defining achievements of modern times it is fair to say that these have had little impact on the fortunes of persons afflicted with Alzheimer’s disease, multiple system atrophy, frontotemporal dementia, and the like. Modest success has been achieved with symptomatic treatment; the best example being the treatment of Parkinson’s disease with L-dopa and dopamine agonists.

Original languageEnglish
Title of host publicationAntisense Drug Technology
Subtitle of host publicationPrinciples, Strategies, and Applications, Second Edition
PublisherCRC Press
Pages721-745
Number of pages25
ISBN (Electronic)9781439832509
ISBN (Print)0849387965, 9780849387968
StatePublished - Jan 1 2007
Externally publishedYes

Fingerprint Dive into the research topics of 'Targeting neurological disorders with antisense oligonucleotides'. Together they form a unique fingerprint.

  • Cite this

    Smith, R. A., & Miller, T. M. (2007). Targeting neurological disorders with antisense oligonucleotides. In Antisense Drug Technology: Principles, Strategies, and Applications, Second Edition (pp. 721-745). CRC Press.